Primary study · included by 1 review

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.

Kao et al. 2022 · Kao Hsiang-Fong, Liao Bin-Chi, Huang Yen-Lin, et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2022

PubMed 35046059 doi:10.1158/1078-0432.ccr-21-3025Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Trial PICO

Not extracted yet. Trial-level population, intervention, comparator, outcomes and design will appear here after the trial extraction run. Until then, the reviews below describe the study.

Results

Not extracted yet. Per-trial results (events, means, effect and weight as each review's forest plot reports them) will appear here after the trial extraction run.

Included by

Gene sequencing applications to combat oral-cavity related disorders: a systematic review with meta-analysis.

Non-Cochrane · prognostic · 2024 · cited as Kao et al. 2022 · Table 1 [45]; Figs. 3 and 4 (meta-analysis; non-significant in Fig. 3); observational; ref 45 (Clin Cancer Res 2022)

Outcome this study informs	Pooled effect	Evidence	Certainty
Noticeable impact of gene sequencing on diagnosing/managing oral conditions Gene sequencing (GS) applied to diagnose/manage oral conditions (predominantly 16S rRNA next-generation sequencing of the oral microbiome; also genome-wide/whole-genome sequencing) vs Negligible ('abysmal') effect of gene sequencing; no separate comparator arm (within-sample event contrast in the forest plots)	RR 0.50 [0.46, 0.54]	8 studies · 2211 participants	Ungraded
Noticeable impact of gene sequencing on diagnosing/managing oral conditions Gene sequencing (GS) applied to diagnose/manage oral conditions (predominantly 16S rRNA next-generation sequencing of the oral microbiome; also genome-wide/whole-genome sequencing) vs Negligible ('abysmal') effect of gene sequencing; no separate comparator arm (within-sample event contrast in the forest plots)	OR 0.30 [0.26, 0.33]	8 studies · 2211 participants	Ungraded
Reduction in occurrence of oral conditions Gene sequencing (GS) applied to diagnose/manage oral conditions (predominantly 16S rRNA next-generation sequencing of the oral microbiome; also genome-wide/whole-genome sequencing) vs Negligible ('abysmal') effect of gene sequencing; no separate comparator arm (within-sample event contrast in the forest plots)	RD -0.29 [-0.32, -0.26]	8 studies · 2211 participants	Ungraded

1 including review in total.